Detalhe da pesquisa
1.
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.
Oncologist
; 20(4): 368-9, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25795637
2.
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Future Oncol
; 10(2): 219-31, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24490608
3.
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Invest New Drugs
; 31(5): 1283-93, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23625328
4.
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Clin Cancer Res
; 21(12): 2737-44, 2015 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25370464
5.
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
J Clin Oncol
; 29(28): 3798-804, 2011 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-21859991
6.
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
J Clin Oncol
; 28(25): 3965-72, 2010 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-20679611